Condition (MeSH)
Nasal Obstruction
ClinicalTrials.gov lists 169 trials for Nasal Obstruction or a narrower condition beneath it. Aerin Medical has the most among industry and government lead sponsors, with 10.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
169 of the 169 trials are tagged with Nasal Obstruction itself; the rest are tagged with a narrower condition beneath it.
When did Nasal Obstruction trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 12
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 12 |
| 2025 | 8 |
| 2024 | 9 |
| 2023 | 10 |
| 2022 | 11 |
| 2021 | 10 |
| 2020 | 12 |
| 2019 | 8 |
| 2018 | 6 |
| 2017 | 7 |
Showing 10 of 24 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 14 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 32 months from start to primary completion across 13 trials still running at the 2026-10-09 snapshot; registered median of 13 months across 122 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Nasal Obstruction trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 3 |
| Phase 2 | 12 |
| Phase 2/3 | 1 |
| Phase 3 | 20 |
| Phase 4 | 17 |
| Not applicable | 84 |
| Observational | 27 |
How many Nasal Obstruction trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 8 |
| Recruiting | 13 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 5 |
| Completed | 104 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Nasal Obstruction trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Aerin Medical | 10 |
| GlaxoSmithKline | 6 |
| Third Wave Therapeutics | 4 |
| Ache Laboratorios Farmaceuticos S.A. | 3 |
| Bayer | 3 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Nasal Obstruction? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Bilastine | 3 |
| Pseudoephedrine | 2 |
| Oxymetazoline | 2 |
| AVIGAN | 2 |
| Xylometazoline | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Group 1 | 2 |
| Cetirizine drops | 2 |
| Diphenhydramine 5% | 2 |
| Levocetirizine only | 2 |
| Group 2 | 2 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Nasal Obstruction trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 6 | 2 |
| Respiratory failure | 6 | 1 |
| Acute respiratory distress syndrome | 4 | 1 |
| Chronic Obstructive Pulmonary Disease | 4 | 1 |
| Renal failure acute | 4 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Nasal Obstruction? (234)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Internal Nasal Valve Collapse Treatment by Endonasal Hyaluronic Acid Injection. | Aesthetic plastic surgery | 2025 | Yes |
| Temperature-Controlled Radiofrequency Treatment of the Nasal Valve in Patients With Nasal Obstruction: Long-Term Outcomes. | Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | 2025 | Yes |
| Acoustic resonance therapy is safe and effective for the treatment of nasal congestion in rhinitis: A randomized sham-controlled trial. | International forum of allergy & rhinology | 2024 | Yes |
| Two-year outcomes of radiofrequency device treatment of the nasal valve for nasal airway obstruction. | Rhinology | 2024 | Yes |
| Objective nasal airflow measures in relation to subjective nasal obstruction, trigeminal function, and olfaction in patients with chronic rhinosinusitis. | Rhinology | 2024 | Yes |
Showing 5 of 234 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.